ATG presents epitope-mapping advance to BioValley event
Press Release | ATG:biosynthetics GmbH
MARCH 09, 2017
Merzhausen, Germany: – German-based pre-clinical contract research organization ATG:biosynthetics (ATG) will use the tri-national BioValley Companies Day in late March to present its latest Epitope Mapping Service.
Dr. Adrien Eberlin, Project Manager and Lab Manager in ATG’s R&D Department will represent the company at the BioValley Freiburg event and will talk in the 1150hrs slot on ‘PepID-focused BioDesign of peptides for epitope mapping microarrays in vaccine development by genome analysis.’
The lecture describes ATG’s novel Epitope mapping service that combines computational analysis of a pathogen genome with PepID biopeptides expression technology. The new methodology aims to maximize the efficacy of multi-epitope vaccines.
Powerful PepID algorithms
The powerful PepID computational algorithms allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.
“The new workflow reduces the complexity of the library while conserving the biodiversity of the peptides,” commented ATG:biosynthetics CEO, Dr. Hubert S. Bernauer, who played a leading role in developing the new library design system.
“Such reduction of complexity considerably reduce the cost and time of global epitope mapping project including the entire surfome of the pathogen to be targeted,” Dr. Bernauer explained.
ATG initially developed its peptide library for epitope mapping to support 2013 and 2014 research projects aiming to identify origins and human antibody responses to the West Nile Virus (WNV).
Subsequently, as part of the MycoSynVac consortium, ATG has developed a new workflow that drastically reduces the number of peptides to test in compiling an optimal list.
The presentation will also acknowledge the contribution of Dr. Josef Maier of Information Services to Life Science (IStLS), a long-term partner of ATG that develops bioinformatic tools for the company.
When combined with powerful PepID computational algorithms, these allow ATG to generate deterministic DNA-encoded peptide libraries that can then be submitted to antibody recognition, either by colony immunoblotting or using synthetic peptide microarrays.
“We believe our peers at BioValley will be very interested to hear about this powerful new research tool,” said Dr. Eberlin.
“We are now bringing epitope-mapping to market and will be communicating more intensively on this advanced ATG service during the course of 2017,” said Dr. Eberlin.
About ATG: biosynthetics
ATG :biosynthetics is a German-based pre-clinical contract research company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.
ATG:biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway engineering) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.
ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.
About BioValley Companies Day
BioValley Companies Day is a tri-national market place for business contacts and networking covering the life sciences industries of Germany, Switzerland and France.
The English-language event offers a unique opportunity for companies to present their best offers, innovations and opportunities to their peers, with extensive networking opportunities for discussion and face-to-face meetings.
BioValley companies Day 2017 is a one-day event held between 0900 and 1800 on March 28 at the Tagungscenter ETAGE SolarInfoCenter in Freiburg, Germany.
The event is organized by BioValley Deutschland e.V. with more information at: https://www.gesundheitsindustrie-bw.de/en/event/6-biovalley-companies-day/
Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424
Dr. Josef Maier, IStLS Information Services to Life Science
Tel: +49 (0)7423-8772786
Click on ATG presents epitope-mapping advance to BioValley event for more information.
Click on MycoSynVac for further information.
Click on ATG to contact the company directly.